首页> 外文期刊>Analytical methods >Glycosylation profiling of selected proteins in cerebrospinal fluid from Alzheimer's disease and healthy subjects
【24h】

Glycosylation profiling of selected proteins in cerebrospinal fluid from Alzheimer's disease and healthy subjects

机译:来自阿尔茨海默病和健康受试者的脑脊液中所选蛋白质的糖基化分析

获取原文
获取原文并翻译 | 示例
           

摘要

Alteration of glycosylation has been observed in several diseases, such as cancer and neurodegenerative disorders. The study of changes in glycosylation could lead to a better understanding of mechanisms underlying these diseases and to the identification of new biomarkers. In this work the N-linked glycosylation of five target proteins in cerebrospinal fluid (CSF) from Alzheimer's disease (AD) patients and healthy controls have been analyzed for the first time. The investigated proteins, transferrin (TFN), alpha-1-antitrypsin (AAT), C1-inhibitor, immunoglobulin G (IgG), and alpha-1-acid glycoprotein (AGP), were selected based on the availability of VHH antibody fragments and their potential involvement in neurodegenerative and inflammation diseases. AD patients showed alterations in the glycosylation of low abundance proteins, such as C1-inhibitor and alpha-1-acid glycoprotein. These alterations would not have been detected if the glycosylation profile of the total CSF had been analyzed, due to the masking effect of the dominant profiles of high abundance glycoproteins, such as IgG. Information obtained from single proteins was not sufficient to correctly classify the two sample groups; however, by using an advanced multivariate technique a total non-error rate of 72 +/- 3% was obtained. In fact, the corresponding model was able to correctly classify 71 +/- 4% of the healthy subjects and 74 +/- 7% of the AD patients. Even if the results were not conclusive for AD, this approach could be extremely useful for diseases in which glycosylation changes are reported to be more extensive, such as several types of cancer and autoimmune diseases.
机译:在几种疾病中观察到糖基化的改变,例如癌症和神经变性障碍。对糖基化变化的研究可能导致更好地了解这些疾病的潜在机制以及鉴定新的生物标志物。在这项工作中,第一次分析了来自阿尔茨海默病(AD)患者的脑脊液(CSF)中的五个靶蛋白的n键合糖基化,并进行了健康对照。根据VHH抗体片段的可用性选择,选择所研究的蛋白质,转铁蛋白(TFN),α-1-抗抗糖尿液(AAT),C1抑制剂,免疫球蛋白G(IgG)和α-1-酸糖蛋白(AGP)。他们潜在参与神经变性和炎症疾病。 AD患者显示出低丰度蛋白的糖基化的改变,例如C1抑制剂和α-1-酸糖蛋白。如果已经分析了总CSF的糖基化曲线,则不会检测到这些改变,因为高丰度糖蛋白如IgG的显性曲线的掩蔽效果。从单一蛋白质获得的信息不足以正确分类两个样品组;但是,通过使用高级多变量技术,获得了72 +/- 3%的总非错误率。实际上,相应的模型能够正确分类71 +/- 4%的健康受试者和74 +/- 7%的AD患者。即使结果没有结论广告,这种方法也可能对据报道糖基化变化更广泛的疾病非常有用,例如若干类型的癌症和自身免疫疾病。

著录项

  • 来源
    《Analytical methods》 |2019年第26期|共10页
  • 作者单位

    Stockholm Univ Dept Environm Sci &

    Analyt Chem S-10691 Stockholm Sweden;

    Stockholm Univ Dept Environm Sci &

    Analyt Chem S-10691 Stockholm Sweden;

    Stockholm Univ Dept Environm Sci &

    Analyt Chem S-10691 Stockholm Sweden;

    Univ Sapienza Dept Chem Ple Aldo Moro 5 I-00185 Rome Italy;

    Uppsala Univ Mol Geriatr Rudbeck Lab Dept Publ Hlth &

    Caring Sci S-75185 Uppsala Sweden;

    Stockholm Univ Dept Environm Sci &

    Analyt Chem S-10691 Stockholm Sweden;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分析化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号